Nonsteroidal

China Oncology Drugs Market Research Report 2024-2028 Featuring Major Players - Bristol Myers Squibb, Merck, Eli Lilly, Sino BioPharma, F Hoffmann-La Roche, Johnson & Johnson, AbbVie, AstraZeneca - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 20, 2024
Pharmaceutical, Health, Oncology, Diabetes, Collection, Capsule, Pollutant, Lung cancer, Immunotherapy, Ache, Nonsteroidal anti-inflammatory drug, Smoking, Obesity, Cancer, Prostate, Insight, PRC, Death, Health care, Nonsteroidal, Element, Control, Medicine, SFDA, Molina Healthcare, Patient, Pinnacle, Breast, Risk, Infection, Research, Pharmaceutical industry

High treatment expenses, inadequate insurance, and lack of know-how may also prevent sufferers' capacity to get hold of better oncology treatments in China.

Key Points: 
  • High treatment expenses, inadequate insurance, and lack of know-how may also prevent sufferers' capacity to get hold of better oncology treatments in China.
  • 2.3 Million Oncology deaths are pronounced in China, making Oncology liable for approximately 1 of 5th of all-purpose deaths within the China.
  • NSAIDs (Nonsteroidal Anti-Inflammatory Drugs) and other rising remedies are poised to dominate ChinaOncology drugs market, securing the highest market proportion.
  • This shift signifies a dynamic panorama in China Oncology drugs market, reflecting a growing attention on revolutionary procedures and a broader commitment to preventing oncology comprehensively.

Osteoarthritis Therapeutics Market to grow by USD 3.96 billion from 2022-2027, North America to account for 32% of market growth - Technavio

Retrieved on: 
Wednesday, January 17, 2024
Obesity, X-ray, Regenerative medicine, Osteoarthritis, Risk, Therapy, Research, MRI, Pressure, ROW, Analgesic, NSAID, Health, Pain management, FREE, Nonsteroidal anti-inflammatory drug, Disease, Pfizer, Eli Lilly, Nonsteroidal, Drug development, USD, Ulcer, Burns, Biomarker, DSM-IV codes, Inflammation, Rheumatology, Ageing, Growth, Pharmaceutical industry

NEW YORK, Jan. 16, 2024 /PRNewswire/ -- The osteoarthritis therapeutics market size is expected to grow by USD 3.96 billion from 2022 to 2027.

Key Points: 
  • NEW YORK, Jan. 16, 2024 /PRNewswire/ -- The osteoarthritis therapeutics market size is expected to grow by USD 3.96 billion from 2022 to 2027.
  • North America will contribute 32% to the growth of the global market during the forecast period.
  • Such diagnostic advancements not only aid in understanding drug effectiveness but also drive growth in the osteoarthritis therapeutics market.
  • Growth of the osteoarthritis therapeutics market across North America, Europe, Asia, and ROW
    Comprehensive analysis of factors that will challenge the growth of osteoarthritis therapeutics market vendors.

Veru Announces the Presentation of Positive Phase 2 Clinical Data of Enobosarm in AR+ER+HER2- Metastatic Breast Cancer Patients that Have Progressed on Estrogen Blocking Agents and CDK 4/6 Inhibitor at the ESMO Breast Cancer Congress 2021

Retrieved on: 
Wednesday, May 5, 2021
Chemical compounds, Branches of biology, Drugs, Protein kinase inhibitors, Piperazines, Aromatase inhibitors, Progonadotropins, Cyclin-dependent kinase 4, Oncogenes, Letrozole, Breast cancer, Nonsteroidal

Patients who have metastatic breast cancers that progress on estrogen receptor blocking agent and CDK4/6 inhibitor therapies are a group in which we need to define the most optimal drug treatment.

Key Points: 
  • Patients who have metastatic breast cancers that progress on estrogen receptor blocking agent and CDK4/6 inhibitor therapies are a group in which we need to define the most optimal drug treatment.
  • Enobosarm is in clinical development for the treatment of metastatic ER+HER2- breast cancer patients whose disease has progressed after treatment with a nonsteroidal aromatase inhibitor (anastrozole or letrozole), fulvestrant, and a CDK4/6 inhibitor.
  • In the U.S., FC2 is available by prescription through multiple third-party telemedicine and internet pharmacy providers and retail pharmacies.
  • An NDA was filed by FDA in April 2021 with a PDUFA date in December 2021.